NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer

Tetsuya Nakada; Yuji Noguchi; Shuichiro Satoh; Toshiro Ono; Takashi Saika; Takushi Kurashige; Sacha Gnjatic; Gerd Ritter; Yao Tseng Chen; Elisabeth Stockert; Yasutomo Nasu; Tomoyasu Tsushima; Hiromi Kumon; Lloyd J. Old; Eiichi Nakayama

NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer

Tetsuya Nakada, Yuji Noguchi, Shuichiro Satoh, Toshiro Ono, Takashi Saika, Takushi Kurashige, Sacha Gnjatic, Gerd Ritter, Yao Tseng Chen, Elisabeth Stockert, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old, Eiichi Nakayama

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

Abstract

NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.

Original language	English
Pages (from-to)	1-12
Number of pages	12
Journal	Cancer Immunity
Volume	3
Publication status	Published - Jul 31 2003

Keywords

Human
Immunity
NY-ESO-1
Prostate cancer
RT-PCR
mRNA

ASJC Scopus subject areas

Immunology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{71f4d428871443219c196e65d7d66d05,

title = "NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer",

abstract = "NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.",

keywords = "Human, Immunity, NY-ESO-1, Prostate cancer, RT-PCR, mRNA",

author = "Tetsuya Nakada and Yuji Noguchi and Shuichiro Satoh and Toshiro Ono and Takashi Saika and Takushi Kurashige and Sacha Gnjatic and Gerd Ritter and Chen, {Yao Tseng} and Elisabeth Stockert and Yasutomo Nasu and Tomoyasu Tsushima and Hiromi Kumon and Old, {Lloyd J.} and Eiichi Nakayama",

year = "2003",

month = jul,

day = "31",

language = "English",

volume = "3",

pages = "1--12",

journal = "Cancer immunology research",

issn = "2326-6066",

publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer

AU - Nakada, Tetsuya

AU - Noguchi, Yuji

AU - Satoh, Shuichiro

AU - Ono, Toshiro

AU - Saika, Takashi

AU - Kurashige, Takushi

AU - Gnjatic, Sacha

AU - Ritter, Gerd

AU - Chen, Yao Tseng

AU - Stockert, Elisabeth

AU - Nasu, Yasutomo

AU - Tsushima, Tomoyasu

AU - Kumon, Hiromi

AU - Old, Lloyd J.

AU - Nakayama, Eiichi

PY - 2003/7/31

Y1 - 2003/7/31

N2 - NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.

AB - NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.

KW - Human

KW - Immunity

KW - NY-ESO-1

KW - Prostate cancer

KW - RT-PCR

KW - mRNA

UR - http://www.scopus.com/inward/record.url?scp=3042687137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042687137&partnerID=8YFLogxK

M3 - Article

C2 - 12889868

AN - SCOPUS:3042687137

VL - 3

SP - 1

EP - 12

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

ER -

NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this